Cargando…

Additional Burden Averted in the United States From Use of MF59-Adjuvanted Seasonal Influenza Vaccine Compared With Standard Seasonal Influenza Vaccine Among Adults ≥65 Years

BACKGROUND: The MF59-adjuvanted trivalent inactivated influenza vaccine (aIIV3) is designed to overcome immunosenescence and enhance vaccine responses in older adults. We expanded on the Centers for Disease Control and Prevention (CDC) modeling method to estimate the number of additional influenza-r...

Descripción completa

Detalles Bibliográficos
Autores principales:	McGovern, Ian, Sardesai, Aditya, Taylor, Alexandra, Toro-Diaz, Hector, Haag, Mendel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438869/ https://www.ncbi.nlm.nih.gov/pubmed/37601726 http://dx.doi.org/10.1093/ofid/ofad429

Ejemplares similares

2640. Estimated Additional Burden Averted from Use of Cell-Based Influenza Vaccines Compared to Egg-Based Influenza Vaccines Among People 0-64 Years of Age in the United States: 2017-2020 Seasons
por: McGovern, Ian, et al.
Publicado: (2023)

Effectiveness of the MF59‐adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta‐analysis
por: Coleman, Brenda L., et al.
Publicado: (2021)

Relative Effectiveness of MF59 Adjuvanted Trivalent Influenza Vaccine vs Nonadjuvanted Vaccines During the 2019–2020 Influenza Season
por: Imran, Mahrukh, et al.
Publicado: (2022)

MF59(®)‐adjuvanted vaccines for seasonal and pandemic influenza prophylaxis
por: Banzhoff, Angelika, et al.
Publicado: (2008)

Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine over Three Consecutive Influenza Seasons in the United States
por: Boikos, Constantina, et al.
Publicado: (2022)

AS03- and MF59-Adjuvanted Influenza Vaccines in Children
por: Wilkins, Amanda L., et al.
Publicado: (2017)

Enhanced passive safety surveillance of the MF59-adjuvanted quadrivalent influenza vaccine in the elderly during the 2021/22 influenza season
por: Amicizia, Daniela, et al.
Publicado: (2023)

Enhanced Passive Safety Surveillance (EPSS) confirms an optimal safety profile of the use of MF59(®)‐adjuvanted influenza vaccine in older adults: Results from three consecutive seasons
por: Panatto, Donatella, et al.
Publicado: (2019)

Immunogenicity of standard, high-dose, MF59-adjuvanted, and recombinant-HA seasonal influenza vaccination in older adults
por: Li, Athena P. Y., et al.
Publicado: (2021)

Safety of MF59-Adjuvanted Influenza Vaccination in the Elderly: Results of a Comparative Study of MF59-Adjuvanted Vaccine Versus Nonadjuvanted Influenza Vaccine in Northern Italy
por: Villa, Marco, et al.
Publicado: (2013)

Fluad®-MF59®-Adjuvanted Influenza Vaccine in Older Adults
por: Tsai, Theodore F
Publicado: (2013)

Effectiveness of Cell-Based Quadrivalent Seasonal Influenza Vaccine: A Systematic Review and Meta-Analysis
por: Coleman, Brenda L., et al.
Publicado: (2023)

Review of Analyses Estimating Relative Vaccine Effectiveness of Cell-Based Quadrivalent Influenza Vaccine in Three Consecutive US Influenza Seasons
por: Boikos, Constantina, et al.
Publicado: (2022)

Memory-like innate response to booster vaccination with MF-59 adjuvanted influenza vaccine in children
por: Kazmin, Dmitri, et al.
Publicado: (2023)

902. Incidence of Influenza-Related Medical Encounters Among Adults in The United States During the 2015-2020 Influenza Seasons
por: McGovern, Ian, et al.
Publicado: (2023)

Relative Effectiveness of the Cell-Based Quadrivalent Influenza Vaccine in Preventing Cardiorespiratory Hospitalizations in Adults Aged 18–64 Years During the 2019–2020 US Influenza Season
por: Imran, Mahrukh, et al.
Publicado: (2023)

Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial
por: Mulligan, Mark J., et al.
Publicado: (2014)

Safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine in elderly Chinese subjects
por: Li, Rongcheng, et al.
Publicado: (2008)

Letter to editor regarding the systematic review and meta‐analysis by Coleman et al. on the effectiveness of MF59‐adjuvanted seasonal influenza vaccine in older adults
por: Yin, J. Kevin, et al.
Publicado: (2021)

Estimated Influenza Illnesses and Hospitalizations Averted by Influenza Vaccination — United States, 2012–13 Influenza Season
por: Bresee, Joseph, et al.
Publicado: (2013)

Safety and Immunogenicity of MF59-Adjuvanted Cell Culture–Derived A/H5N1 Subunit Influenza Virus Vaccine: Dose-Finding Clinical Trials in Adults and the Elderly
por: Frey, Sharon E, et al.
Publicado: (2019)

Estimated Influenza Illnesses and Hospitalizations Averted by Vaccination — United States, 2013–14 Influenza Season
por: Reed, Carrie, et al.
Publicado: (2014)

Relative Effectiveness of Adjuvanted Trivalent Inactivated Influenza Vaccine Versus Egg-derived Quadrivalent Inactivated Influenza Vaccines and High-dose Trivalent Influenza Vaccine in Preventing Influenza-related Medical Encounters in US Adults ≥ 65 Years During the 2017–2018 and 2018–2019 Influenza Seasons
por: Boikos, Constantina, et al.
Publicado: (2021)

Investigating the procurement system for understanding seasonal influenza vaccine brand availability in Europe
por: Stuurman, Anke L., et al.
Publicado: (2021)

REAL-WORLD EFFECTIVENESS ENHANCED INFLUENZA VACCINES IN OLDER ADULTS DURING THREE CONSECUTIVE INFLUENZA SEASONS: 2017–2020
por: McGovern, Ian
Publicado: (2022)

Phase 4, Post-Marketing Safety Surveillance of the MF59-Adjuvanted Influenza Vaccines FLUAD(®) and VANTAFLU(®) in South Korean Subjects Aged ≥65 Years
por: Yoo, Byung Wook, et al.
Publicado: (2018)

Immunogenicity and Safety of an MF59-adjuvanted Quadrivalent Seasonal Influenza Vaccine in Young Children at High Risk of Influenza-associated Complications: A Phase III, Randomized, Observer-blind, Multicenter Clinical Trial
por: Esposito, Susanna, et al.
Publicado: (2020)

The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany
por: Kohli, Michele A., et al.
Publicado: (2022)

Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50–64 Years of Age
por: Poder, Airi, et al.
Publicado: (2023)

Intranasal Immunization Using Mannatide as a Novel Adjuvant for an Inactivated Influenza Vaccine and Its Adjuvant Effect Compared with MF59
por: Ren, Shu-Ting, et al.
Publicado: (2017)

Decline in Seasonal Influenza Vaccine Effectiveness With Vaccination Program Maturation: A Systematic Review and Meta-analysis
por: Okoli, George N, et al.
Publicado: (2021)

Deaths averted by influenza vaccination in the U.S. during the seasons 2005/06 through 2013/14()
por: Foppa, Ivo M., et al.
Publicado: (2015)

Effectiveness of the Cell-Derived Inactivated Quadrivalent Influenza Vaccine in Individuals at High Risk of Influenza Complications in the 2018–2019 United States Influenza Season
por: Boikos, Constantina, et al.
Publicado: (2021)

Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older
por: Schwarz, Tino F, et al.
Publicado: (2017)

Global patterns of seasonal influenza activity, duration of activity and virus (sub)type circulation from 2010 to 2020
por: Zanobini, Patrizio, et al.
Publicado: (2022)

Influenza Vaccine Uptake in the United States before and during the COVID-19 Pandemic
por: McGovern, Ian, et al.
Publicado: (2022)

Incidence of Medically Attended Respiratory Syncytial Virus and Influenza Illnesses in Children 6–59 Months Old During Four Seasons
por: Simpson, Melissa D., et al.
Publicado: (2016)

Effectiveness of MF59™ Adjuvanted Influenza A(H1N1)pdm09 Vaccine in Risk Groups in the Netherlands
por: Wijnans, Leonoor, et al.
Publicado: (2013)

Antibody responses to intradermal or intramuscular MF59-adjuvanted influenza vaccines as evaluated in elderly institutionalized volunteers during a season of partial mismatching between vaccine and circulating A(H3N2) strains
por: Camilloni, Barbara, et al.
Publicado: (2014)

Epidemiology and Burden of Influenza in Children 0–14 Years Over Ten Consecutive Seasons in Italy
por: Barbieri, Elisa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mc62nm6k8thb37g084kjtoahsh